The Experts below are selected from a list of 2100 Experts worldwide ranked by ideXlab platform
Erko Stackebrandt - One of the best experts on this subject based on the ideXlab platform.
-
the genus nocardiopsis represents a phylogenetically coherent taxon and a distinct actinomycete lineage proposal of nocardiopsaceae fam nov
International Journal of Systematic and Evolutionary Microbiology, 1996Co-Authors: Fred A. Rainey, Reiner M. Kroppenstedt, Naomi Wardrainey, Erko StackebrandtAbstract:The genus Nocardiopsis was shown to be phylogenetically coherent and to represent a distinct lineage within the radiation of the order Actinomycetales. The closest relatives of the genus Nocardiopsis are members of the genera Actinomadura, Thermomonospora, Streptosporangium, and Microtetraspora. The intrageneric structure of the genus Nocardiopsis is shown to consist of a highly related species group containing Nocardiopsis dassonvillei, Nocardiopsis alborubida, and Nocardiopsis antarctica and a second group of less highly related species comprising Nocardiopsis alba subsp. alba, Nocardiopsis alba subsp. prasina, and Nocardiopsis listeri. Nocardiopsis lucentensis occupies a position intermediate between the two species groups. The results of a 16S ribosomal DNA sequence analysis are generally consistent with the available chemotaxonomic, phenotypic, and DNA-DNA hybridization data. The phylogenetic position and the morpho- and chemotaxonomic properties of Nocardiopsis species support the creation of a family for the genus Nocardiopsis, Nocardiopsaceae fam. nov.
H Guillot - One of the best experts on this subject based on the ideXlab platform.
-
trimethoprim sulfamethoxazole for Nocardiosis in solid organ transplant recipients real life data from a multicentre retrospective study
Transplant Infectious Disease, 2021Co-Authors: Pierrelouis Conan, H Guillot, Giovanna Melica, Steven Van Laecke, Marie Matignon, A Bleibtreu, Henri Brenier, Romain Crochette, Mario Fernandezruiz, Jacques DantalAbstract:Background Little is known regarding the optimal management of Nocardiosis among solid organ transplant (SOT) recipients. It is often suggested to avoid trimethoprim/sulfamethoxazole (TMP-SMX) monotherapy in heavily immunocompromised patients (such as SOT recipients) and/or in case of severe or disseminated Nocardiosis. Our aim was to report our experience with TMP-SMX monotherapy in SOT recipients with Nocardiosis. Methods Using data from a previously published European study, we assessed the incidence of adverse events in SOT recipients receiving TMP-SMX monotherapy and assessed its effectiveness. Results Thirty-one SOT recipients with Nocardiosis were included, mostly kidney transplant recipients (20/31, 65%). Eleven (36%) had disseminated infection, and four (13%) had brain Nocardiosis. Most patients had lung and/or pleural involvement (26/31, 84%). Daily dose of trimethoprim at initiation was 10 [6.4-14.8] mg/kg. The median estimated glomerular filtration rate at time of diagnosis of Nocardiosis was 44 [30-62] ml/min/1.73 m². TMP-SMX was discontinued prematurely in one third of the patients (10/31, 32%, mostly for hematological toxicity [n = 3] or increased serum creatinine [n = 3]). Focusing on the 24 (77%) patients who completed at least 30 days of TMP-SMX monotherapy, 4 had late (>30 days) drug discontinuation, 1 experienced treatment failure, and 19 completed planned TMP-SMX monotherapy. Clinical outcome was favorable in these 19 patients, despite the fact that 8 (42%) had disseminated infection and 2 (11%) brain Nocardiosis. Overall, all-cause 1-year mortality was 10% (3/31). Conclusions TMP-SMX monotherapy appears to be effective for the treatment of most Nocardiosis among SOT recipients. Interventional studies are needed to compare its safety and effectiveness with those of other regimens used to treat posttransplant Nocardiosis.
-
outcome and treatment of Nocardiosis after solid organ transplantation new insights from a european study
Clinical Infectious Diseases, 2017Co-Authors: David Lebeaux, H Guillot, Romain Freund, S D Marbus, Benoit Douvry, Marie Matignon, Christian Van Delden, Eric Van Wijngaerden, Julien De GreefAbstract:Background Solid organ transplant (SOT) recipients are at risk of Nocardiosis, a rare opportunistic bacterial infection, but prognosis and outcome of these patients are poorly defined. Our objectives were to identify factors associated with one-year mortality after Nocardiosis and describe the outcome of patients receiving short-course antibiotics (≤120 days). Methods We analyzed data from a multicenter European case-control study that included 117 SOT recipients with Nocardiosis diagnosed between 2000 and 2014. Factors associated with one-year all-cause mortality were identified using multivariable conditional logistic regression. Results One-year mortality was 10-fold higher in patients with Nocardiosis (16.2%, 19/117) than in control transplant recipients (1.3%, 3/233, p<0.001). A history of tumor (odds ratio [OR] 1.4; 95% confidence interval [CI] 1.1-1.8), invasive fungal infection in the six months before Nocardiosis (OR 1.3; 95%CI 1.1-1.5) and donor age (OR 1.0046; 95%CI 1.0007-1.0083) were independently associated with one-year mortality. Acute rejection in the year before Nocardiosis was associated with improved survival (OR 0.85; 95%CI 0.73-0.98). Seventeen patients received short-course antibiotics (median duration 56 [24-120] days) with a one-year success rate (cured and surviving) of 88% and a 5.9% risk of relapse (median follow-up 49 [6-136] month). Conclusions One-year mortality was 10-fold higher in SOT patients with Nocardiosis than in those without. Four factors, largely reflecting general medical condition rather than severity and/or management of Nocardiosis, were independently associated with one-year mortality. Patients receiving short-course antibiotic treatment had good outcomes, suggesting this may be a strategy for further study.
-
nocardia infection in solid organ transplant recipients a multicenter european case control study
Clinical Infectious Diseases, 2016Co-Authors: Julien Coussement, David Lebeaux, Christian Van Delden, H Guillot, Romain Freund, S D Marbus, Giovanna Melica, Eric Van Wijngaerden, Benoit Douvry, Steven Van LaeckeAbstract:Nocardiosis is a rare, life-threatening opportunistic infection, affecting 0.04% to 3.5% of patients after solid organ transplant (SOT). The aim of this study was to identify risk factors for Nocardia infection after SOT and to describe the presentation of Nocardiosis in these patients.
Jacques Dantal - One of the best experts on this subject based on the ideXlab platform.
-
trimethoprim sulfamethoxazole for Nocardiosis in solid organ transplant recipients real life data from a multicentre retrospective study
Transplant Infectious Disease, 2021Co-Authors: Pierrelouis Conan, H Guillot, Giovanna Melica, Steven Van Laecke, Marie Matignon, A Bleibtreu, Henri Brenier, Romain Crochette, Mario Fernandezruiz, Jacques DantalAbstract:Background Little is known regarding the optimal management of Nocardiosis among solid organ transplant (SOT) recipients. It is often suggested to avoid trimethoprim/sulfamethoxazole (TMP-SMX) monotherapy in heavily immunocompromised patients (such as SOT recipients) and/or in case of severe or disseminated Nocardiosis. Our aim was to report our experience with TMP-SMX monotherapy in SOT recipients with Nocardiosis. Methods Using data from a previously published European study, we assessed the incidence of adverse events in SOT recipients receiving TMP-SMX monotherapy and assessed its effectiveness. Results Thirty-one SOT recipients with Nocardiosis were included, mostly kidney transplant recipients (20/31, 65%). Eleven (36%) had disseminated infection, and four (13%) had brain Nocardiosis. Most patients had lung and/or pleural involvement (26/31, 84%). Daily dose of trimethoprim at initiation was 10 [6.4-14.8] mg/kg. The median estimated glomerular filtration rate at time of diagnosis of Nocardiosis was 44 [30-62] ml/min/1.73 m². TMP-SMX was discontinued prematurely in one third of the patients (10/31, 32%, mostly for hematological toxicity [n = 3] or increased serum creatinine [n = 3]). Focusing on the 24 (77%) patients who completed at least 30 days of TMP-SMX monotherapy, 4 had late (>30 days) drug discontinuation, 1 experienced treatment failure, and 19 completed planned TMP-SMX monotherapy. Clinical outcome was favorable in these 19 patients, despite the fact that 8 (42%) had disseminated infection and 2 (11%) brain Nocardiosis. Overall, all-cause 1-year mortality was 10% (3/31). Conclusions TMP-SMX monotherapy appears to be effective for the treatment of most Nocardiosis among SOT recipients. Interventional studies are needed to compare its safety and effectiveness with those of other regimens used to treat posttransplant Nocardiosis.
Steven Van Laecke - One of the best experts on this subject based on the ideXlab platform.
-
trimethoprim sulfamethoxazole for Nocardiosis in solid organ transplant recipients real life data from a multicentre retrospective study
Transplant Infectious Disease, 2021Co-Authors: Pierrelouis Conan, H Guillot, Giovanna Melica, Steven Van Laecke, Marie Matignon, A Bleibtreu, Henri Brenier, Romain Crochette, Mario Fernandezruiz, Jacques DantalAbstract:Background Little is known regarding the optimal management of Nocardiosis among solid organ transplant (SOT) recipients. It is often suggested to avoid trimethoprim/sulfamethoxazole (TMP-SMX) monotherapy in heavily immunocompromised patients (such as SOT recipients) and/or in case of severe or disseminated Nocardiosis. Our aim was to report our experience with TMP-SMX monotherapy in SOT recipients with Nocardiosis. Methods Using data from a previously published European study, we assessed the incidence of adverse events in SOT recipients receiving TMP-SMX monotherapy and assessed its effectiveness. Results Thirty-one SOT recipients with Nocardiosis were included, mostly kidney transplant recipients (20/31, 65%). Eleven (36%) had disseminated infection, and four (13%) had brain Nocardiosis. Most patients had lung and/or pleural involvement (26/31, 84%). Daily dose of trimethoprim at initiation was 10 [6.4-14.8] mg/kg. The median estimated glomerular filtration rate at time of diagnosis of Nocardiosis was 44 [30-62] ml/min/1.73 m². TMP-SMX was discontinued prematurely in one third of the patients (10/31, 32%, mostly for hematological toxicity [n = 3] or increased serum creatinine [n = 3]). Focusing on the 24 (77%) patients who completed at least 30 days of TMP-SMX monotherapy, 4 had late (>30 days) drug discontinuation, 1 experienced treatment failure, and 19 completed planned TMP-SMX monotherapy. Clinical outcome was favorable in these 19 patients, despite the fact that 8 (42%) had disseminated infection and 2 (11%) brain Nocardiosis. Overall, all-cause 1-year mortality was 10% (3/31). Conclusions TMP-SMX monotherapy appears to be effective for the treatment of most Nocardiosis among SOT recipients. Interventional studies are needed to compare its safety and effectiveness with those of other regimens used to treat posttransplant Nocardiosis.
-
nocardia infection in solid organ transplant recipients a multicenter european case control study
Clinical Infectious Diseases, 2016Co-Authors: Julien Coussement, David Lebeaux, Christian Van Delden, H Guillot, Romain Freund, S D Marbus, Giovanna Melica, Eric Van Wijngaerden, Benoit Douvry, Steven Van LaeckeAbstract:Nocardiosis is a rare, life-threatening opportunistic infection, affecting 0.04% to 3.5% of patients after solid organ transplant (SOT). The aim of this study was to identify risk factors for Nocardia infection after SOT and to describe the presentation of Nocardiosis in these patients.
Xiangcheng Dai - One of the best experts on this subject based on the ideXlab platform.
-
primary cutaneous Nocardiosis due to nocardia farcinica a case report of an often overlooked infection
Infection and Drug Resistance, 2021Co-Authors: Siyu Gao, Qiang Liu, Xiaolin Zhou, Xiangcheng DaiAbstract:Primary cutaneous Nocardiosis by Nocardia farcinica is exceedingly rare. Only six cases have been reported from PubMed in the past 15 years. We encounter such a case in a 55-year-old man receiving long-term steroid and cyclophosphamide. Owing to no characteristic symptoms, the disease can be so easily overlooked and causes fatal consequences. Therefore, we herein discuss common features of primary cutaneous Nocardiosis by Nocardia farcinica that remind clinicians considering it.
